Annalisa Ruggeri

Annalisa Ruggeri

Auto-generated profile, based on publicly available information

Annalisa Ruggeri

IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Haematology and Bone Marrow Transplantation, Milano, Italy

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2010 in The Lancet Oncology
Verified
Journal Article
Closed access
MEMary Eapen
Mary Eapen
VRVanderson Rocha
Vanderson Rocha
Guillermo F SanzGuillermo F Sanz
Guillermo F Sanz
ASAndromachi Scaradavou
Andromachi Scaradavou
MZMei-Jie Zhang
Mei-Jie Zhang
JWJohn E Wagner
John E Wagner

16 March 2017 in Blood
Verified
Journal Article
Open access
PDF file
EGEliane Gluckman
Eliane Gluckman
BCBarbara Cappelli
Barbara Cappelli
FBFrancoise Bernaudin
Francoise Bernaudin
MLMyriam Labopin
Myriam Labopin
FVFernanda Volt
Fernanda Volt
MEMary Eapen
Mary Eapen
Key Points: HLA-identical sibling transplantation for SCD offers excellent long-term survival. Mortality risk is higher for older patients; event-free survival has improved in patients transplanted after 2006.

14 December 2015 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
ARA Ruggeri
A Ruggeri
MLM Labopin
M Labopin
FCF Ciceri
F Ciceri
MMM Mohty
M Mohty
ANA Nagler
A Nagler
Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP–EBMT analysis on patients with AML in remission

2 January 2014 in Blood
Verified
Journal Article
Closed access
PDF file
MEMary Eapen
Mary Eapen
JKJohn P. Klein
John P. Klein
ARAnnalisa Ruggeri
Annalisa Ruggeri
SSStephen Spellman
Stephen Spellman
SLStephanie J. Lee
Stephanie J. Lee
VRVanderson Rocha
Vanderson Rocha
Key Points: Efficacy of transplanting allele-level HLA-matched cord blood units.

8 August 2013 in Blood
Verified
Journal Article
Closed access
PDF file
FLFranco Locatelli
Franco Locatelli
NKNabil Kabbara
Nabil Kabbara
ARAnnalisa Ruggeri
Annalisa Ruggeri
AGArdeshir Ghavamzadeh
Ardeshir Ghavamzadeh
IRIrene Roberts
Irene Roberts
EGEurocord and European Blood and Marrow Transplantation (EBMT) group
Eurocord and European Blood and Marrow Transplantation (EBMT) group
We analyzed the outcomes of 485 patients with thalassemia major (TM) or sickle cell disease (SCD) receiving HLA-identical sibling cord blood transplantation (CBT, n = 96) or bone marrow transplantation (BMT, n = 389). Compared with patients given BMT, CBT recipients were significantly younger (median age 6 vs 8 years, P = .02), and were treated more recently (median year 2001 vs 1999, P < .01). A higher proportion of patients with TM belonging to classes II-III of the Pesaro classification received BMT (44%) compared with CBT (39%, P < .01). In comparison with patients receiving BMT (n = 259, TM; n = 130, SCD), those given CBT (n = 66, TM; n = 30, SCD) had slower neutrophil recovery, less acute graft-versus-host disease (GVHD) and none had extensive chronic GVHD. With a median follow-up of 70 months, the 6-year overall survival was 95% and 97% after BMT and CBT, respectively (P = .92). The 6-year disease-free survival (DFS) was 86% and 80% in TM patients after BMT and CBT, respectively, whereas DFS in SCD patients was 92% and 90%, respectively. The cell dose infused did not influence outcome of patients given CBT. In multivariate analysis, DFS did not differ between CBT and BMT recipients. Patients with TM or SCD have excellent outcomes after both HLA-identical sibling CBT and BMT. Key Points Patients with thalassemia major or sickle cell disease had excellent outcomes after both CBT and BMT from an HLA-identical sibling. Related cord blood transplantation is a suitable transplant option for patients with hemoglobinopathies.

17 April 2015 in Leukemia
Verified
Journal Article
Closed access
PDF file
ARA Ruggeri
A Ruggeri
MLM Labopin
M Labopin
GSG Sanz
G Sanz
SPS Piemontese
S Piemontese
WAW Arcese
W Arcese
MMM Mohty
M Mohty